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Objectives: Vaccination would lead to reduce the incidence and mortality of an 
infectious disease and then increase the years of life and productivity for entire 
society. But, determination of vaccination coverage rate is usually not taken its 
economic burden into account. This study aims to use a transmission dynamic 
model (TDM) based on a susceptible-infectious-recovered (SIR) model, a system of 
differential equations, to find optimal vaccination coverage rate based on the eco-
nomic burden of an infectious disease. MethOds: Vaccination for pneumococcus 
diseases was used as an example to demonstrate the main purpose. 23-valent pneu-
mococcal polysaccharide vaccines (PPV23) and13-valent pneumococcal conjugate 
vaccines (PCV13) have been shown their cost-effectiveness in elderly and children, 
respectively. Scenarios analysis of PPV23 to the elderly aged 65+ years and PCV13 to 
children 5 years and under was applied to assess the optimal vaccination coverage 
rate based on the economic burden. All epidemiological parameters were derived 
from the Taiwan’s National Health Insurance Research Database, all cost parameter 
were derived from the Taiwan’s Ministry of the Interior and the vaccine efficacy 
was obtained from the literatures. Various vaccination coverage rate, the vaccine 
efficacy and all epidemiological parameters were all substituted into to TDM and 
all differential equations were solved using the fourth-order Runge–Kutta method 
implemented in R Statistical Software. Results: If the he coverage rate of PPV23 for 
the elderly and PCV23 for the children both reach to 50%, the economic burden due 
to pneumococcus disease will be minimized approximately. cOnclusiOns: This 
study provided an alternative perspective from the economic burden of diseases 
to obtain a vaccination coverage rate using the TDM. This will provide valuable 
information for vaccination policy decision makers.
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Objectives: Decision makers are frequently faced with the question of how realis-
tic are cost-effectiveness models. Overall survival (OS) is a desired clinical trial and 
health technology assessment endpoint but frequently unrealistic or elusive at the 
point of new drugs financing decision. We aim to compare the overall survival from 
lenalidomide treatment in relapsed/refractory multiple myeloma (rrMM) patients 
estimated from modelling clinical trial data in a cost-effectiveness analysis (CEA) 
and compare it with real-word data (RWD) from South Korea. MethOds: In this 
CEA of lenalidomide-plus-dexamethasone OS outcomes were indirectly estimated 
using a quantitative relationship between time-to-progression/progression-free-
survival derived with a censored normal weighted Tobit regression model with 
data from a literature review of 153 studies containing 230 treatment arms and 
22,696 MM patients. Real world data was from a retrospective analysis of 110 heavily 
pre-treated patients from 20 hospitals.  These patients were treated with lenalid-
omide-plus-dexamethasone in the Korean patient access program between 2008 
and 2012. Results: The RWD was available for a heavily pre-treated population 
with 76.3% of patients with > 2 previous treatments. For this population, estimated 
median time to progression (TTP) was 7 and 7.4 months in RWD and MM009/010 
clinical trials, respectively. Corresponding predicted Tobit model upfront OS esti-
mates, corrected for baseline characteristics, were 21.3 and 22.2 months. In the RWD 
data from South-Korea the reported median OS was 21 months. Median OS was also 
21.0 months in the equivalent population of the two large, multicenter MM009/010 
randomized phase III trials. cOnclusiOns: This study provides evidence that over-
all survival of Lenalidomide-plus-dexamethasone treatment in relapsed/refractory 
multiple myeloma estimated in a cost-effectiveness analysis is remarkably similar 
to the outcomes observed in real-word patients and points to the value of such 
upfront estimates to decision makers in the absence of mature overall survival data.
PRM21
coMPaRing The eVenT PReDicTion caPaBiliTy of The UKPDs68 anD hong 
Kong DiaBeTes RisK eqUaTions WiThin a TyPe 2 DiaBeTes siMUlaTion 
MoDel
McEwan P.1, Ward T.2, Bennett H.2, Bergenheim K.3
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2Health Economics and Outcomes 
Research Ltd, Monmouth, UK, 3AstraZeneca, Mölndal, Sweden
Objectives: There is concern over the ability of cardiovascular risk equations to 
reliably predict event incidence across contrasting populations, specifically when 
considering ethnic variation. The UKPDS68 and Hong Kong (HK) risk equations 
have been extensively validated, and are derived from UK and Chinese popula-
tions, respectively. The objective of this study was to compare the predicted incre-
mental event incidence for different diabetes treatments in a Chinese population, 
when using the UKPDS68 and HK risk equations within an established diabetes 
model. MethOds: Treatment with SGLT2 inhibitor or sulfonylurea (SU), combined 
with metformin, was modelled in a cohort of 1,000 patients over variable time 
horizons. Baseline clinical inputs and treatment effects utilised in the model were 
obtained from published literature. Treatment effects were applied to the follow-
ing modifiable risk factors: HbA1c, blood pressure, cholesterol and eGFR. Chinese 
life tables were employed to model all-cause mortality. Incidence of both CHD and 
stroke events were compared. Results: Modelled treatment effects corresponded 
to one predictive risk factor contained in each of the HK equations, compared to four 
in each of the UKPDS68 equations.  When comparing treatment with SGLT2 inhibitor 
to SU using the UKPDS68 equations, the incremental incidence of stroke and CHD 
Korea, Taiwan, Australia, Japan, and Singapore. We assessed the use of databases 
in studies relevant to health economics and outcomes research (HEOR) on the 
use of antidepressants. MethOds: A literature search was conducted to include 
English language articles in PubMed to identify  database analysis studies  from 
2000-2013. We identified the number of studies from these countries using the 
databases as well as their  topics of focus. These included studies on  prescription 
patterns, resource use and cost of disease. Results: From the countries included 
in the study, Taiwan had the highest number of studies published on HEOR and 
the use of antidepressants. There were very few or no studies from Japan, South 
Korea, Australia and Singapore. The topics ranged from the use of antidepressants, 
prevalence, use among adolescents, and factors associated with persistence or 
early attrition to treatment. Some studies documented the clinical or economic 
impact of continuous treatment. cOnclusiOns: Viewed in the context of the 
earlier study on availability of accessibility of databases, it appears that Taiwan 
has a high degree of usage based on the number of publications found in our 
second phase. This may be due to some advantages in terms of database acces-
sibility, transparency of processes and representativeness of the population. As 
such, for the purpose of research and improving understanding of disease, the 
authors feel that the Taiwan database is a good example especially for countries 
still developing their database capabilities.
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Objectives: Patients, physician behaviors, and health systems differ across 
regions. Models without features to account for heterogeneity can’t be readily 
adapted in AP region. Warfarin, the standard care for stroke prevention in atrial 
fibrillation patients, requires routine monitoring of International Normalized Ratio 
(INR). Below or above the target range (2.0-3.0) increases ischemic or hemorrhagic 
events, respectively. Time in therapeutic range (TTR) determines therapeutic 
effectiveness. INR monitoring and increased hemorrhagic risk created barriers 
for broad effective warfarin use in AP region. The mean TTR in US was 66.7%. 
In contrast, the estimate was 36% in China. All existing anticoagulant models, 
mostly Markov-based, have no explicit INR modeling.  To allow for effectiveness 
projections for warfarin in AP settings, our model incorporated an INR mod-
ule. MethOds: We adopted a microsimulation approach to accommodate the 
patient heterogeneity and the strong association between a patient’s history and 
future outcomes. An INR control module was built in three steps: a) estimated 
event rates within target INR range, b) probabilistically chose an INR range for a 
patient at each cycle based on the simulated population’s TTR distribution, and 
c) projected event rates at the chosen INR range by incorporating the relative 
risks of INR control effect on events. Inputs were derived from the RE-LY trial, 
published literature and expert opinion. Results: We performed internal vali-
dation by projecting 2-year clinical events using the RE-LY-like TTR distribution 
(22.2% INR< 2.0, 64.4% 2.0≤ INR≤ 3.0 13.4% INR> 3.0), achieving events rates similar 
to those observed in RE-LY. Applying a China-like TTR distribution (59% INR< 2.0, 
36% 2.0≤ INR≤ 3.0, 5% INR> 3.0) increased ischemic event rates while reducing hem-
orrhagic event rates. cOnclusiOns: Explicitly modeling INR control produced 
realistic projections which allowed adaptation of our anticoagulant model to AP 
settings. Proactively incorporating flexible model structure to accommodate het-
erogeneity was an efficient approach to improve model generalizability.
PRM18
sTRaTegies To oVeRcoMe hURDles in hTa aPPRaisals aMiD liMiTaTions 
ResUlTing fRoM single-aRM TRial DaTa
Xenakis A.1, Beckerman R.2
1CBPartners, New York City, NY, USA, 2CBPartners, New York, NY, USA
Objectives: The purpose of this study was to evaluate the barriers that arise in 
constructing strong pharmacoeconomic (PE) submission based on evidence from 
single-arm clinical trials, and to evaluate strategies to overcome them. MethOds: 
A set of therapeutics were selected based on the following criteria: oncology indica-
tion with a PE submission for health technology assessment (HTA) review, utilis-
ing single-arm trial data. HTA appraisals in five major markets were considered 
– GBR, CAN, SCT, GER, and FRA. Modelling approaches used in each appraisal were 
enumerated, and HTA body comments on each employed strategy were collected. 
Each identified modelling strategy was evaluated for its likelihood in overcoming 
a negative appraisal across the selected major markets. Results: The PE model 
barriers associated with single-arm trial data included: lack of direct comparison 
with comparator, reliance on surrogate endpoints, and lack of long-term follow-up. 
The techniques employed to address these drawbacks included: comparison with 
historical control, comparison with self-control, comparison with non-responder 
control, comparison with placebo-arm of a published trial, correlation of surro-
gate endpoints to hard outcomes, survival extrapolation methodology (including 
parametric extrapolation and cumulative survival approach). These methods were 
most successful in FRA and CAN, where positive HTA appraisals were awarded 7/8 
and 2/2 times, respectively; and were least successful in GBR and SCT, where posi-
tive HTA appraisals were awarded 1/4 and 2/8 times, respectively. cOnclusiOns: 
Manufacturers may face difficulties when modelling a product’s economic benefit 
based on data from a single-arm trial. While securing a positive HTA appraisal for 
such PE submissions remains difficult, there exist strategies that can help to over-
come identified barriers, which have led to success in major HTA markets – most 
notably FRA and CAN.
